{
    "organizations": [],
    "uuid": "14f90b80d9f320275951a912eb380025dba6dac2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-thrombogenics-announces-positive-p/brief-thrombogenics-announces-positive-preclinical-data-on-thr-149-idUSFWN1RI0TC",
    "ord_in_thread": 0,
    "title": "BRIEF-Thrombogenics Announces Positive Preclinical Data On THR-149",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 6 (Reuters) - THROMBOGENICS NV:\n* ANNOUNCES THAT POSITIVE PRECLINICAL DATA ON PLASMA KALLIKREIN (PKAL) INHIBITORS IN DIABETIC MACULAR EDEMA (DME) HAVE BEEN PUBLISHED IN JOURNAL OF MEDICINAL CHEMISTRY\n* POSITIVE OUTCOMES OF PKAL INHIBITORS ON TISSUE EDEMA SUPPORTS THEIR DEVELOPMENT AS POSSIBLE TREATMENTS FOR DME AND DR VIA A VEGF-INDEPENDENT MECHANISM\n* PRECLINICAL STUDY CONFIRMED THAT BICYCLIC PEPTIDES HAVE NANOMOLAR TO PICOMOLAR POTENCIES, ARE STABLE IN BIOLOGICAL MATRICES AND REPORTED PROLONGED RETENTION IN EYE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-06T13:45:00.000+03:00",
    "crawled": "2018-04-07T16:15:55.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "thrombogenics",
        "nv",
        "announces",
        "positive",
        "preclinical",
        "data",
        "plasma",
        "kallikrein",
        "pkal",
        "inhibitor",
        "diabetic",
        "macular",
        "edema",
        "dme",
        "published",
        "journal",
        "medicinal",
        "chemistry",
        "positive",
        "outcome",
        "pkal",
        "inhibitor",
        "tissue",
        "edema",
        "support",
        "development",
        "possible",
        "treatment",
        "dme",
        "dr",
        "via",
        "mechanism",
        "preclinical",
        "study",
        "confirmed",
        "bicyclic",
        "peptide",
        "nanomolar",
        "picomolar",
        "potency",
        "stable",
        "biological",
        "matrix",
        "reported",
        "prolonged",
        "retention",
        "eye",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}